05-16-07



TFW

Application ( ( 10/594,773

Attorney Docket No.: 66368(46590)

## Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. EV971741711US in an envelope addressed to:

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

on May 15, 2007

Date

Signatu	re
Denise Bror	nsdon
Typed or printed name of per	rson signing Certificate
	(617) 517-5595
Registration Number, if applicable	Telephone Number

Note:

Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

IDS (Citation) by Applicant (13 References) (1 page) Information Disclosure Statement (2 pages)



Docket No.: 66368(46590)

(PATENT)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Hiroshi Inooka et al.

Application No.: 10/594,773

Filed: September 29, 2006

Art Unit: N/A

Confirmation No.:

For: ANTIBODY DRUG

Examiner: Not Yet Assigned

## **INFORMATION DISCLOSURE STATEMENT (IDS)**

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

A full translation of the non-English language references is enclosed.

In accordance with 37 CFR 1.98(a)(2)(ii), Applicant has not submitted copies of U.S. patents and U.S. patent applications. Applicant submits herewith copies of foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR

Application No.: 10/594,773 2 Docket No.: 66368(46590)

1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 04-1105, under Order No. 66368(46590). A duplicate copy of this paper is enclosed.

Dated: May 15, 2007

Respectfully submitted,

Gregory B. Butler, Ph.D., Esq. Registration No.: 34,558

EDWARDS ANGELL PALMER & DODGE

LLP

P.O. Box 55874

Boston, Massachusetts 02205

(617) 517-5595

Attorneys/Agents For Applicant

PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Red rsons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO Application Number 10/594,773 INFORMATION DISCLOSURE September 29, 2006 Filing Date STATEMENT BY APPLICANT First Named Inventor Hiroshi Inooka Art Unit N/A (Use as many sheets as necessary) **Examiner Name** Not Yet Assigned of Sheet 1 1 Attorney Docket Number 66368(46590)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2</sup> ( if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

		FOREI	GN PATENT	DOCUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	1
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				T⁵
	BA	WO-91/12022	08-22-1991	Takeda Chemical Industries, Ltd.		
	BB	WO-91/14786	10-03-1991	Takeda Chemical Industries, Ltd.		
	ВС	WO-2005/094881 A1	13.10.2005	Takeda Pharmaceutical Co., Ltd.		$\Box$
	BD	WO-85/00974	14.03.1985	Hybritech., Inc.		
	BE	WO-96/00284	04.01.96	Behringwerke Aktiengesellschaft		
	BF	EP-0 467 416 A1	22.01.1992	Hybritech, Inc.		
	BG	EP-0 298 654 B1	01.06.1994	Hybrisens, Ltd.		
	ВН	JP-04-120025	21.04.1992	Tosoh Corp et al.		
	ВІ	WO-85/00974 (JP-60-502104)	14.03.1985	Hybritech, Inc.		
	BJ	JP-01-138 461 A2	05-31-1989	Hybrisens, Ltd.		
	вк	JP-03-133378	08-26-1997	Kwan et al.		
		(US 5,660,978)				
	BL	JP-10-504708	01-04-2000	Neuenhofer et a.		$\Box$
		(US 6,010,868)				1 1

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>8</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
	CA	Suzuki, et al. (1993) Production of Immunoreactive Pituitary Adenylate Cyclase Activiting Polypeptide (PACAP) by Human Neuroblastoma Cells, IMR-32: Detection and Characterization with Monoclonal and Polyclonal Antibodies Against Different Epitocpes of PACAP. <i>J. Biochem, 113,</i> 549-556.		

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner	Date
	Date
Signature	Considered
	Considered
607499	